Comparing NIVF and NIVFW: Shares and Warrants of NewGenIvf Group Limited
Key Takeaways
- NIVF and NIVFW are two securities of the same issuer: NewGenIvf Group Limited. One is the company's ordinary shares, the other is its publicly traded equity warrants.
- NewGenIvf has pivoted from its legacy fertility services into digital assets, AI (K25.ai), real estate, and cell-sorting technology, reshaping its risk profile.
- Both securities have been highly volatile, with the shares trading far below their 52-week high after a series of reverse stock splits and repeated equity raises.
- A recent $1.25 million public offering, priced at $0.07 per share, has pressured the share price and diluted existing holders.
- The warrants carry leverage and a 2029 expiry, meaning their value is tightly linked to the underlying shares but with different risk dynamics.
Introduction
Investors comparing NIVF and NIVFW are not weighing two competing companies, but two different instruments tied to the same business: NewGenIvf Group Limited. This stock comparison is especially relevant for traders assessing relative performance and market positioning within one name. The ordinary shares represent direct equity ownership, while the warrants offer a leveraged, time-limited claim on the same underlying company. Understanding the distinctions in business context, momentum, and risk is essential for anyone deciding which instrument better suits their strategy in the current market environment.
NIVF at a Glance and Recent Moves
NIVF is the Class A ordinary share listing of NewGenIvf Group Limited, a diversified holding company headquartered in Bangkok. Its legacy business is in vitro fertilization (IVF) and assisted reproductive services across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. In recent periods, management has repositioned the company as a "tech-forward" growth entity, adding segments in digital assets, real estate development in the UAE, and health products, along with a strategic stake in K25.ai, an AI-powered prediction-market platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent market activity has been turbulent. The company priced and closed a roughly $1.25 million public offering in recent weeks, selling shares and pre-funded warrants at $0.07 each, with proceeds earmarked for the K25.ai investment, debt restructuring, and deployment of Nodexus cell-sorting machines. Dilutive raises and a long sequence of reverse stock splits have compressed the share count and price, leaving the shares trading near the low end of a 52-week range that reflects repeated split adjustments. Sentiment has been shaped by Nasdaq listing-compliance pressures, a low market capitalization relative to reported net asset value, and uncertainty around the company's rapid strategic pivot.
NIVFW at a Glance and Recent Moves
NIVFW represents the publicly traded equity warrants of NewGenIvf Group Limited. A warrant gives the holder the right — but not the obligation — to purchase the underlying ordinary shares at a specified price before a set date; these particular warrants carry an expiration date in April 2029. As a result, the warrants are a derivative of the same business described above, rather than an independent operating company.
The warrants have traded in a narrow band in recent months, generally moving in the low single-digit cent range and sitting closer to their 52-week low than their high. Because warrant pricing is driven primarily by the underlying share price, time to expiry, and implied volatility, recent equity raises and share-price weakness have weighed on the warrants as well. Their thin trading volume and low nominal price make them more sensitive to percentage swings, a characteristic that can appeal to short-term traders while introducing additional execution risk.
Head-to-Head Comparison
The central distinction in this stock comparison is instrument type rather than company identity. NIVF offers direct equity exposure: shareholders participate in the issuer's value, carry voting and economic rights, and face dilution from recurring offerings and the possibility of further reverse splits. Its growth narrative now spans fertility, AI, digital assets, and real estate — a diversified but hard-to-value mix.
NIVFW, by contrast, is a leveraged, time-limited option on that same equity. It offers greater percentage upside potential if the shares rally meaningfully, but it also decays in value if the underlying stagnates and can go to zero at expiry. The warrants do not pay dividends and their liquidity is thinner. Risk factors are shared — Nasdaq compliance, dilution, execution of the strategic pivot — but the warrants amplify both the rewards and the downside. Sector exposure is identical; only the payoff structure differs.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and relative positioning, Tickeron's AI would likely view both instruments cautiously in the current environment. A persistent downtrend, repeated dilution, and unresolved listing-compliance risks argue against a decisive bullish signal. Between the two, a probabilistic assessment would tend to favor the ordinary shares (NIVF) over the warrants for most investors, because the shares carry no expiry date and avoid the leverage and time-decay risks embedded in NIVFW. However, any signal would remain conditional on a durable trend reversal and clearer confirmation from catalysts such as the K25.ai investment or improved compliance standing.
Using AI Tools for My Research
In my analysis of complex situations like this, I often turn to Tickeron’s AI Trading Bots to test systematic approaches across volatile names. The platform hosts hundreds of algorithmic strategies that monitor thousands of tickers, each with distinct styles, timeframes, and performance histories. Only those best suited to current conditions appear in trending sections, which helps filter the noise when evaluating instruments like warrants versus shares. Explore the Trending AI Robots page to see which strategies are currently standing out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
NIVF's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NIVF turned positive on October 02, 2026. Looking at past instances where NIVF's MACD turned positive, the stock continued to rise in 11 of 11 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +13.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in 66 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NIVF as a result. In 38 of 38 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIVF entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.031) is normal, around the industry mean (208.195). P/E Ratio (0.001) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement